Zacks Research Has Positive Estimate for A Q1 Earnings

Agilent Technologies, Inc. (NYSE:A) – Zacks Research boosted their Q1 2026 earnings estimates for shares of Agilent Technologies in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $1.39 per share for the quarter, up from their prior forecast of $1.35. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.47 EPS.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird dropped their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Sanford C. Bernstein lowered their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $135.00 to $145.00 in a research report on Monday, February 10th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Price Performance

A stock opened at $120.72 on Monday. Agilent Technologies has a 12 month low of $117.17 and a 12 month high of $155.35. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average price of $136.74 and a 200 day moving average price of $137.28. The stock has a market cap of $34.42 billion, a PE ratio of 27.75, a P/E/G ratio of 3.39 and a beta of 1.11.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The firm had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in Agilent Technologies by 1.2% during the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock valued at $1,903,498,000 after purchasing an additional 158,175 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Agilent Technologies by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company’s stock worth $1,250,276,000 after acquiring an additional 59,781 shares during the period. Geode Capital Management LLC increased its stake in shares of Agilent Technologies by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company’s stock worth $938,291,000 after acquiring an additional 53,992 shares during the period. Pictet Asset Management Holding SA increased its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company’s stock worth $700,414,000 after acquiring an additional 47,495 shares during the period. Finally, Deutsche Bank AG increased its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company’s stock worth $596,026,000 after acquiring an additional 38,348 shares during the period.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the transaction, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This trade represents a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.82%. Agilent Technologies’s payout ratio is presently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.